Ceftazidime-Avibactam Resistance in Sequence Type 11 Due to a Mutation in Plasmid-Borne to , in Henan, China

Overview

Journal Infect Drug Resist

Publisher Dove Medical Press

Date 2021 May 19

PMID 34007191

Citations 13

Authors

Debao Li

Keyang Li

Hongliang Dong

Dongmei Ren

Dandan Gong

Fuguo Jiang

Chunhua Shi

Junmin Li

Qi Zhang

Wenjuan Yan

Yi Li

Affiliations

Soon will be listed here.

Abstract

Purpose: Carbapenem-resistant (CRKP) represents a serious problem worldwide. Herein, we describe the evolution of ceftazidime-avibactam (CZA) resistance by sequencing clinical isolates from a patient with CRKP infection undergoing CZA treatment.

Patients And Methods: In this study, six CRKP strains were isolated from sputum and blood samples of a patient with CRKP infection after intracerebral hemorrhage. Two strains were selected for whole-genome analysis.

Results: Drug susceptibility testing showed that the MIC of CZA for CRKP strains isolated after 6 days of CZA treatment was 64-fold higher than that for three CRKP strains isolated before CZA treatment (4 vs >256 μg/mL), whereas the MIC of imipenem and meropenem was 128-fold (>32 vs 0.25 μg/mL) and 16-fold (> 32 vs 2 μg/mL) lower relatively, respectively. Multilocus sequence typing showed that all six CRKP strains isolated from the patient were ST11 and pulsed-field gel electrophoresis confirmed that they were of the same clone. Two strains were selected for whole-genome analysis. The aspartic acid residue at position 179 in the Ω loop was replaced by a tyrosine residue in the resistant strain, and the plasmid carried a to mutation. The results of the modified carbapenem inactivation method and the carbapenemase inhibitor enhancement and colloidal gold enzyme immunochromatographic assays for were negative.

Conclusion: This is the first report from Henan to show that treatment with CZA for 6 days can cause mutations and change the phenotype from CZA sensitive to resistant. Therefore, routine testing for drug susceptibility and carbapenemase phenotypes should be conducted during treatment with CZA, and genotype determination is essential.

Citing Articles

Ceftazidime-avibactam tolerance and persistence among difficult-to-treat KPC-producing Klebsiella pneumoniae clinical isolates from bloodstream infections.

Abichabki N, Gaspar G, Bortolato L, Lima D, Silva L, Pocente R Eur J Clin Microbiol Infect Dis. 2024; 44(2):343-353.

PMID: 39614972 DOI: 10.1007/s10096-024-05005-4.

Ceftazidime-avibactam treatment dilemma of bla-containing Klebsiella pneumoniae due to the development of co-existence of mixed strains carrying bla or bla in lung transplant recipients.

Lei Z, Li Z, Zhang Y, Zeng L, Wu Y, Zhang F Ann Clin Microbiol Antimicrob. 2024; 23(1):99.

PMID: 39516891 PMC: 11549737. DOI: 10.1186/s12941-024-00743-x.

Retrospective Tertiary Care-Based Cohort Study on Clinical Characteristics and Outcomes of Ceftazidime-Avibactam-Resistant Carbapenem-Resistant Infections.

Ahmed F, Abraham B, Saeed N, Mohamed Naser H, Sridharan K Crit Care Res Pract. 2024; 2024:3427972.

PMID: 38868174 PMC: 11168800. DOI: 10.1155/2024/3427972.

Molecular mechanisms responsible KPC-135-mediated resistance to ceftazidime-avibactam in ST11-K47 hypervirulent .

Shi Q, Shen S, Tang C, Ding L, Guo Y, Yang Y Emerg Microbes Infect. 2024; 13(1):2361007.

PMID: 38801099 PMC: 11172257. DOI: 10.1080/22221751.2024.2361007.

ST11 KPC-2-Producing Isolated from Patient with Acute Myelocytic Leukemia.

Chen C, Yang F, Chen M, Xu Y, Xie Y, Liu R Infect Drug Resist. 2024; 17:51-59.

PMID: 38205063 PMC: 10778216. DOI: 10.2147/IDR.S441479.

References

Li H, Durbin R . Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009; 25(14):1754-60. PMC: 2705234. DOI: 10.1093/bioinformatics/btp324. View

Compain F, Arthur M . Impaired Inhibition by Avibactam and Resistance to the Ceftazidime-Avibactam Combination Due to the DY Substitution in the KPC-2 β-Lactamase. Antimicrob Agents Chemother. 2017; 61(7). PMC: 5487616. DOI: 10.1128/AAC.00451-17. View

Lahiri S, Bradford P, Nichols W, Alm R . Structural and sequence analysis of class A β-lactamases with respect to avibactam inhibition: impact of Ω-loop variations. J Antimicrob Chemother. 2016; 71(10):2848-55. DOI: 10.1093/jac/dkw248. View

Xu L, Sun X, Ma X . Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017; 16(1):18. PMC: 5371217. DOI: 10.1186/s12941-017-0191-3. View

Giddins M, Macesic N, Annavajhala M, Stump S, Khan S, McConville T . Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in -Harboring Klebsiella pneumoniae Sequence Type 307 Isolates. Antimicrob Agents Chemother. 2017; 62(3). PMC: 5826117. DOI: 10.1128/AAC.02101-17. View

Shields R, Potoski B, Haidar G, Hao B, Doi Y, Chen L . Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections. Clin Infect Dis. 2016; 63(12):1615-1618. PMC: 5146720. DOI: 10.1093/cid/ciw636. View

Bortolaia V, Kaas R, Ruppe E, Roberts M, Schwarz S, Cattoir V . ResFinder 4.0 for predictions of phenotypes from genotypes. J Antimicrob Chemother. 2020; 75(12):3491-3500. PMC: 7662176. DOI: 10.1093/jac/dkaa345. View

Gaibani P, Campoli C, Lewis R, Volpe S, Scaltriti E, Giannella M . In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment. J Antimicrob Chemother. 2018; 73(6):1525-1529. DOI: 10.1093/jac/dky082. View

Bianco G, Boattini M, van Asten S, Iannaccone M, Zanotto E, Zaccaria T . RESIST-5 O.O.K.N.V. and NG-Test Carba 5 assays for the rapid detection of carbapenemase-producing Enterobacterales from positive blood cultures: a comparative study. J Hosp Infect. 2020; 105(2):162-166. DOI: 10.1016/j.jhin.2020.03.022. View

10.

Shields R, Chen L, Cheng S, Chavda K, Press E, Snyder A . Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections. Antimicrob Agents Chemother. 2016; 61(3). PMC: 5328542. DOI: 10.1128/AAC.02097-16. View

11.

Oueslati S, Iorga B, Tlili L, Exilie C, Zavala A, Dortet L . Unravelling ceftazidime/avibactam resistance of KPC-28, a KPC-2 variant lacking carbapenemase activity. J Antimicrob Chemother. 2019; 74(8):2239-2246. DOI: 10.1093/jac/dkz209. View

12.

Levitt P, Papp-Wallace K, Taracila M, Hujer A, Winkler M, Smith K . Exploring the role of a conserved class A residue in the Ω-Loop of KPC-2 β-lactamase: a mechanism for ceftazidime hydrolysis. J Biol Chem. 2012; 287(38):31783-93. PMC: 3442512. DOI: 10.1074/jbc.M112.348540. View

13.

Kim D, Ahn J, Lee C, Jang S, Lee H, Yong D . Increasing Resistance to Extended-Spectrum Cephalosporins, Fluoroquinolone, and Carbapenem in Gram-Negative Bacilli and the Emergence of Carbapenem Non-Susceptibility in Klebsiella pneumoniae: Analysis of Korean Antimicrobial Resistance Monitoring.... Ann Lab Med. 2017; 37(3):231-239. PMC: 5339095. DOI: 10.3343/alm.2017.37.3.231. View

14.

Bianco G, Boattini M, Iannaccone M, Cavallo R, Costa C . Bloodstream infection by two subpopulations of Klebsiella pneumoniae ST1685 carrying KPC-33 or KPC-14 following ceftazidime/avibactam treatment: considerations regarding acquired heteroresistance and choice of carbapenemase detection assay. J Antimicrob Chemother. 2020; 75(10):3075-3076. DOI: 10.1093/jac/dkaa283. View

15.

Gaibani P, Lewis R, Volpe S, Giannella M, Campoli C, Landini M . In vitro interaction of ceftazidime-avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates. Int J Infect Dis. 2017; 65:1-3. DOI: 10.1016/j.ijid.2017.09.017. View

16.

Shirley M . Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections. Drugs. 2018; 78(6):675-692. DOI: 10.1007/s40265-018-0902-x. View

17.

Daikos G, Tsaousi S, Tzouvelekis L, Anyfantis I, Psichogiou M, Argyropoulou A . Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother. 2014; 58(4):2322-8. PMC: 4023796. DOI: 10.1128/AAC.02166-13. View

18.

Shi Q, Yin D, Han R, Guo Y, Zheng Y, Wu S . Emergence and Recovery of Ceftazidime-avibactam Resistance in blaKPC-33-Harboring Klebsiella pneumoniae Sequence Type 11 Isolates in China. Clin Infect Dis. 2020; 71(Suppl 4):S436-S439. DOI: 10.1093/cid/ciaa1521. View

19.

Tsakris A, Poulou A, Pournaras S, Voulgari E, Vrioni G, Themeli-Digalaki K . A simple phenotypic method for the differentiation of metallo-beta-lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical isolates. J Antimicrob Chemother. 2010; 65(8):1664-71. DOI: 10.1093/jac/dkq210. View

20.

Zhang R, Liu L, Zhou H, Chan E, Li J, Fang Y . Nationwide Surveillance of Clinical Carbapenem-resistant Enterobacteriaceae (CRE) Strains in China. EBioMedicine. 2017; 19:98-106. PMC: 5440625. DOI: 10.1016/j.ebiom.2017.04.032. View